Building the Future of Drug Discovery (Dr. Jeff Reid)

Sooner or later everyone is touched by disease. With this hard fact in mind, over the past 30 years, we at
Regeneron have done everything we can to bring science to medicine and develop therapeutics to
improve health outcomes for everyone. Towards this end, in 2014 we launched the “Regeneron
Genetics Center” and embarked on one of the largest sequencing efforts in the world to bring the
genomics revolution to drug development with the goal of making important new medicines informed
by human genetics and validated using our best-in- class mouse genetics technologies.

Because of the scale of sequencing needed to discover and validate the impact of rare functionally
important genetic variants, we knew we would need one of the largest genomic data science efforts
ever conceived to enable the RGC. Our early large-scale data strategy has already paid off with a new
drug target for chronic liver disease*, but knowing that there are many more insights to be gained from
our rapidly growing TB-scale dataset of more than 80B data points, we turned to the Databricks Unified
Analytics Platform to provide both scalability so that we can work in every disease area simultaneously,
and enable users at all levels of expertise in the drug development teams to gain insights from our
massive volume of diverse data. We know that having the data is just the first step, enabling drug
development teams to answer questions with the data is how we are building the future of drug discovery.

About: Databricks provides a unified data analytics platform, powered by Apache Spark™, that accelerates innovation by unifying data science, engineering and business.

Connect with us: